Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 8/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.78 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085572 | 0.90 | CYP2C9 (0.83) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL1183390 | 0.89 | CYP2C9 (0.62) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL52691 | 0.88 | CYP2C9 (1.00) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL28640238 | 0.87 | CYP2C9 (0.98) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL3219153 | 0.87 | CYP2C9 (0.98) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL6938534 | 0.86 | CYP2C9 (0.64) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL22614693 | 0.83 | CYP2C9 (0.54) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL247490 | 0.82 | CYP2C9 (0.78) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL14439966 | 0.82 | CYP2C9 (0.89) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| Etravirine SCHEMBL1085342 | 0.82 | CYP2C9 (0.88) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480483-A | Preparation method of etravirine chloro impurities | 浙江致新医药科技有限公司 | 2021-10-08 | — | — | CN | claimed |
| US-20200345733-A1 | Microbicidal Pyrimidine or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-05 | — | — | US | claimed |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2017-04-13 | — | — | US | claimed |
| EP-1282607-B1 | PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-11 | — | — | EP | claimed |
| US-8003789-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-08-23 | — | — | US | claimed |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-07-07 | — | — | US | claimed |
| US-7935710-B2 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-05-03 | — | — | US | claimed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | claimed |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-24 | — | — | US | claimed |
| EP-1505980-B1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARM LTD (IE) | 2007-10-24 | — | — | EP | claimed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | claimed |
| US-20060166943-A1 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-07-27 | — | — | US | claimed |
| US-7034019-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-25 | — | — | US | claimed |
| EP-1225874-B1 | ANTIVIRAL SOLID DISPERSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | EP | claimed |
| US-20060009474-A1 | Prodrugs of HIV replication inhibiting pyrimidines | KUKLA MICHAEL J | 2006-01-12 | — | — | US | claimed |
| EP-1505980-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | Tibotec Pharmaceuticals Ltd. (IE) | 2005-02-16 | — | — | EP | claimed |
| WO-2003094920-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-20 | — | — | WO | claimed |
| EP-1214300-B1 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO KG (DE) | 2003-09-03 | — | — | EP | claimed |
| EP-1002795-B1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-05 | — | — | EP | claimed |
| CN-113480483-A | Preparation method of etravirine chloro impurities | 浙江致新医药科技有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113480483-A | Preparation method of etravirine chloro impurities | 浙江致新医药科技有限公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-1648467-B1 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL | JANSSEN SCIENCES IRELAND UC (IE) | 2018-03-21 | — | — | EP | disclosed |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2017-04-13 | — | — | US | disclosed |
| US-9427400-B2 | Platinum-catalyzed intravaginal rings | INTERNATIONAL PARTNERSHIP FOR MICROBICIDES (US) | 2016-08-30 | — | — | US | disclosed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| EP-1282607-B1 | PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-11 | — | — | EP | disclosed |
| US-9028876-B2 | Rate-controlled particles | JANSSEN R&D IRELAND (IE) | 2015-05-12 | — | — | US | disclosed |
| US-8722696-B2 | Process for preparing particles containing an antiviral | JANSSEN R&D IRELAND (IE) | 2014-05-13 | — | — | US | disclosed |
| US-20140056961-A1 | PLATINUM-CATALYZED INTRAVAGINAL RINGS | INTERNATIONAL PARTNERSHIP FOR MICROBICIDES (US) | 2014-02-27 | — | — | US | disclosed |
| US-8580294-B2 | Platinum-catalyzed intravaginal rings | INTERNATIONAL PARTNERSHIP FOR MICROBICIDES (US) | 2013-11-12 | — | — | US | disclosed |
| US-8530655-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-20120172364-A1 | RATE-CONTROLLED PARTICLES | JANSSEN R&D IRELAND (IE) | 2012-07-05 | — | — | US | disclosed |
| US-20120093911-A1 | PLATINUM-CATALYZED INTRAVAGINAL RINGS | INTERNATIONAL PARTNERSHIP FOR MICROBICIDES (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | CORTE BART DE | 2011-10-27 | — | — | US | disclosed |
| US-8003789-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-08-23 | — | — | US | disclosed |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-07-07 | — | — | US | disclosed |
| US-7935710-B2 | Microbicidal pyrimidine or triazine for preventing sexual HIV transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-05-03 | — | — | US | disclosed |
| US-7763631-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| US-20100062069-A1 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL | JANSSEN SCIENCES IRELAND UC (IE) | 2010-03-11 | — | — | US | disclosed |
| US-20090148531-A1 | RATE-CONTROLLED PARTICLES | JANSSEN R&D IRELAND (IE) | 2009-06-11 | — | — | US | disclosed |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1505980-B1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARM LTD (IE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | disclosed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-20060172010-A1 | Process for preparing particles containing an antiviral | ETHYPHARM SA (FR) | 2006-08-03 | — | — | US | disclosed |
| US-20060166943-A1 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-07-27 | — | — | US | disclosed |
| US-7037917-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| EP-1648467-A1 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL | Tibotec Pharmaceuticals Ltd. (IE) | 2006-04-26 | — | — | EP | disclosed |
| US-7034019-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-25 | — | — | US | disclosed |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| EP-1225874-B1 | ANTIVIRAL SOLID DISPERSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | EP | disclosed |
| US-20060009474-A1 | Prodrugs of HIV replication inhibiting pyrimidines | KUKLA MICHAEL J | 2006-01-12 | — | — | US | disclosed |
| US-20050288278-A1 | HIV replication inhibiting pyrimidines | CORTE BART DE | 2005-12-29 | — | — | US | disclosed |
| EP-1567134-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-31 | — | — | EP | disclosed |
| US-6878717-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-12 | — | — | US | disclosed |
| EP-1505980-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | Tibotec Pharmaceuticals Ltd. (IE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005011702-A1 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004050068-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050058-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | disclosed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | disclosed |
| WO-2003094920-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-20 | — | — | WO | disclosed |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, INC. | 2003-10-02 | — | — | US | disclosed |
| EP-1214300-B1 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO KG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-20030114472-A1 | Viricides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| EP-1002795-B1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1270560-A1 | Hiv replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1225874-A1 | ANTIVIRAL COMPOSITIONS | Janssen Pharmaceutica N.V. (BE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001022938-A1 | ANTIVIRAL COMPOSITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-05 | — | — | WO | disclosed |
| EP-1002795-A1 | HIV Replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000027825-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027825-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345733-A1 | Microbicidal Pyrimidine or Triazine Containing Compounds | SAMHD1, NT5C2, TK1 | CYP2C9 1801/4885CYP2C19 991/4885KCNH2 3776/4885 |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | SLC10A1, SLC7A1, SLC26A4 | CYP2C9 258/4885CYP2C19 247/4885KCNH2 4042/4885 |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | CYP2C9 2076/4885CYP2C19 1690/4885KCNH2 4091/4885 |
| US-20100062069-A1 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL | SSRP1, SAMHD1, TYMP | CYP2C9 1790/4885CYP2C19 1174/4885KCNH2 2550/4885 |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | ABCC1, MGAT1, RRM2 | CYP2C9 1440/4885CYP2C19 1598/4885KCNH2 1795/4885 |
| US-20030114472-A1 | Viricides | ZC3HAV1, ZC3HAV1L, POLR2H | CYP2C9 1103/4885CYP2C19 2432/4885KCNH2 328/4885 |
| US-20170100399-A1 | Microbicidal Pyrimidine Or Triazine Containing Compounds | SAMHD1, NT5C2, TK1 | CYP2C9 1903/4885CYP2C19 1091/4885KCNH2 3806/4885 |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | NSUN2, CCNO, POLR2H | CYP2C9 778/4885CYP2C19 783/4885KCNH2 1658/4885 |
| US-20050288278-A1 | HIV replication inhibiting pyrimidines | NSUN2, POLR2H, CCNO | CYP2C9 867/4885CYP2C19 849/4885KCNH2 1614/4885 |
| US-20120093911-A1 | PLATINUM-CATALYZED INTRAVAGINAL RINGS | PCNA, DPYD, QDPR | CYP2C9 568/4885CYP2C19 457/4885KCNH2 2817/4885 |
| US-20090148531-A1 | RATE-CONTROLLED PARTICLES | APOB, CCNB2, CYP2C19 | CYP2C9 54/4885CYP2C19 3/4885KCNH2 1976/4885 |
| US-20110165093-A1 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION | SAMHD1, NT5C2, TPMT | CYP2C9 1465/4885CYP2C19 689/4885KCNH2 3464/4885 |
| US-20140056961-A1 | PLATINUM-CATALYZED INTRAVAGINAL RINGS | PCNA, DPYD, QDPR | CYP2C9 568/4885CYP2C19 457/4885KCNH2 2817/4885 |
| US-20120172364-A1 | RATE-CONTROLLED PARTICLES | APOB, CCNB2, CYP2C19 | CYP2C9 54/4885CYP2C19 3/4885KCNH2 1976/4885 |
| US-20060172010-A1 | Process for preparing particles containing an antiviral | SSRP1, SAMHD1, TYMP | CYP2C9 1790/4885CYP2C19 1174/4885KCNH2 2550/4885 |
| US-20060166943-A1 | Microbicidal pyrimidine or triazine for preventing sexual hiv transmission | SAMHD1, NT5C2, TPMT | CYP2C9 1405/4885CYP2C19 651/4885KCNH2 3478/4885 |
| US-20030186990-A1 | Prodrugs of hiv replication inhibiting pyrimidines | CYP2S1, REV1, CYP1B1 | CYP2C9 229/4885CYP2C19 237/4885KCNH2 4045/4885 |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | CYP2C9 2076/4885CYP2C19 1690/4885KCNH2 4091/4885 |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | CPN1, CTRL, HPN | CYP2C9 1966/4885CYP2C19 2829/4885KCNH2 1433/4885 |
| US-20060009474-A1 | Prodrugs of HIV replication inhibiting pyrimidines | REV1, CYP2S1, ADORA1 | CYP2C9 207/4885CYP2C19 161/4885KCNH2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.